Company Overview

Zenith Drugs Limited is a pharmaceutical company incorporated in 2000, specializing in the manufacturing and trading of high-quality, affordable medicines, including generic drugs. Originally incorporated as "Zenith Drugs Private Limited" on November 15, 2000, it was converted into a Public Limited Company and renamed "Zenith Drugs Limited" on September 13, 2023. The company is headquartered in Indore, Madhya Pradesh.

With over two decades of service, Zenith Drugs has established itself as a trusted pharmaceutical manufacturing unit among healthcare practitioners and government institutions. Its manufacturing unit holds the prestigious WHO-GMP certification, affirming its commitment to international quality standards. The company also possesses ISO 9001:2015 certification from a respected EuroUK certification body.

Business Operations and Product Portfolio

The core business of Zenith Drugs involves the manufacturing and trading of medicines. The company offers a diverse range of formulations across various forms, including ORS powder, liquid oral, ointments, creams, gels, liquid externals, capsules, and tablets. Zenith operates dedicated manufacturing lines for Oral Liquids, External Liquids, External Semisolids, Oral Powders, Capsules (Hard Gelatin), and has Injectables under construction.

The company's state-of-the-art facility in Indore produces over 250 molecules and 780 SKUs. The Food & Drugs Administration has approved more than 600 products, with 325 currently in production. Zenith has developed particular expertise in manufacturing Oral Rehydration Salt (ORS) and is recognized as one of the largest manufacturers of ORS sachets in Central India.

Zenith Drugs has built strong relationships with reputable pharmaceutical companies. Its product quality is trusted by major players such as Ajanta Pharma, Micro Labs, May & Bakers, and Kopran. The company is also recognized by more than 10 Indian state governments as a consistent supplier. Domestically, Zenith is expanding its presence through its wholly-owned subsidiaries, Biozen Healthcare and Biogenesis Corporation.

Stock Market Performance and Valuation

Zenith Drugs Limited successfully listed on the NSE SME platform on February 27, 2024, following a bookbuilding IPO worth ₹40.68 crores, comprising entirely of a fresh issue of 51.49 lakh shares. As of July 2025, the market capitalization of Zenith Drugs Ltd is ₹121.76 crores.

The stock trades under the symbol ZENITHDRUG on the NSE. Its 52-week high is ₹154.40, and the 52-week low is ₹47.15. Currently, the stock trades at a Price-to-Earnings (P/E) ratio of 17.01 and a Price-to-Book (P/B) ratio of 1.95.

Financial Performance

Based on recent financial data, Zenith Drugs reported a profit of ₹9.56 crores and a revenue of ₹130 crores. On a trailing 12-month basis, the company's operating revenue stands at ₹334.35 crores. Zenith has achieved an annual revenue growth of 16%, maintained a pre-tax margin of 11%, and an Return on Equity (ROE) of 15%. The company maintains a healthy balance sheet with a debt-to-equity ratio of 14%.

However, the company is experiencing some working capital challenges. It has high debtors (187 days), and its working capital days have increased from 103 days to 155 days. For the financial year 2024, Zenith Drugs did not declare any dividend (₹0.0 per share).

Key Financial Metrics

- Recent Revenue & Profit: ₹130 Crores (Revenue), ₹9.56 Crores (Profit)

- Trailing 12-Month Operating Revenue: ₹334.35 Crores

- Annual Revenue Growth: 16%

- Pre-Tax Margin: 11%

- Return on Equity (ROE): 15%

- Debt-to-Equity Ratio: 14%

- Market Capitalization: ₹121.76 Crores (As of July 2025)

- Promoter Holding: 69.98% (As of March 2025)

- P/E Ratio: 17.01

- P/B Ratio: 1.95

- Working Capital Days: 155 days (Increased from 103 days)

- Debtors Days: 187 days

Business Operations and Production Capacity

Zenith Drugs specializes in manufacturing and trading a wide array of pharmaceutical formulations. The company's product range includes ORS powder, liquid oral preparations, ointments, creams, gels, liquid externals, capsules, and tablets. Its manufacturing facility is equipped with dedicated lines for Oral Liquids, External Liquids, External Semisolids, Oral Powders, and Hard Gelatin Capsules. Additionally, Injectables manufacturing capabilities are currently under construction.

The Indore-based facility is highly productive, capable of producing over 250 distinct molecules and 780 Stock Keeping Units (SKUs). Products to the tune of 600 have received approval from the Food & Drugs Administration, with 325 currently in active production. Zenith has cemented its position as a leading manufacturer of Oral Rehydration Salt (ORS) sachets in the central India region.

The company's commitment to quality is evidenced by its WHO-GMP certification and ISO 9001:2015 certification. Zenith has cultivated strong partnerships with leading pharmaceutical firms like Ajanta Pharma, Micro Labs, May & Bakers, and Kopran. It also serves as a trusted, consistent supplier to government institutions across more than 10 Indian states. Zenith's domestic market expansion is driven by its wholly-owned subsidiaries, Biozen Healthcare and Biogenesis Corporation.

Shareholding Pattern and Corporate Governance

As of March 2025, the promoter group holds a substantial 69.98% stake in Zenith Drugs Limited, with no promoter shares pledged. In terms of corporate governance, Sakshi Bhawsar serves as the company secretary. The company's statutory auditor is VDS & Co.

Recent Corporate Developments

Zenith Drugs Limited has recently submitted its financial results for the period ending March 31, 2025, to the Exchange. In April 2025, the company secured significant government tenders valued at ₹7.10 crores in Rajasthan and ₹94.45 lacs in Madhya Pradesh. The company's board convened in April 2025 to discuss crucial matters including potential fund raising and an increase in authorized capital.

Zenith Drugs Limited represents a growing pharmaceutical entity with robust manufacturing capabilities and a proven track record in securing government tenders. The company's adherence to stringent quality certifications, a diverse product portfolio, and established relationships with major pharmaceutical companies strategically position it within the competitive pharmaceutical sector. While mindful of the working capital management challenges, Zenith's consistent growth trajectory and strong promoter holding signal promising potential for sustained development in the Indian pharmaceutical market.